New transplant combo aims to tame Graft-Versus-Host disease
NCT ID NCT03192397
First seen Apr 20, 2026 · Last updated Apr 30, 2026 · Updated 3 times
Summary
This study tests a stem cell transplant method for people with blood cancers like leukemia or lymphoma. The approach combines chemotherapy and radiation before transplant with a drug called cyclophosphamide after transplant to lower the risk of graft-versus-host disease, where donor cells attack the patient's body. About 35 adults in remission or with certain blood disorders are taking part. The goal is to see if this method improves outcomes while reducing serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
Conditions
Explore the condition pages connected to this study.